Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by equities research analysts at Canaccord Genuity from a “buy” rating to a “hold” rating in a report released on Wednesday, The Fly reports.
A number of other brokerages also recently commented on REGN. Citigroup reissued a “buy” rating and set a $480.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Thursday, November 9th. BMO Capital Markets lowered their price objective on Regeneron Pharmaceuticals from $491.00 to $479.00 and set a “market perform” rating for the company in a research report on Thursday, November 9th. Piper Jaffray Companies reissued a “buy” rating and set a $540.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, November 13th. Royal Bank of Canada reissued a “sector perform” rating and set a $425.00 price objective (down from $473.00) on shares of Regeneron Pharmaceuticals in a research report on Thursday, November 9th. Finally, JPMorgan Chase & Co. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, October 31st. Three analysts have rated the stock with a sell rating, fifteen have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Regeneron Pharmaceuticals has an average rating of “Hold” and a consensus price target of $457.03.
Regeneron Pharmaceuticals (REGN) opened at $323.04 on Wednesday. The firm has a market capitalization of $35,771.23, a PE ratio of 31.30, a price-to-earnings-growth ratio of 1.04 and a beta of 1.47. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.82 and a quick ratio of 3.18. Regeneron Pharmaceuticals has a 52-week low of $313.53 and a 52-week high of $543.55.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, topping the Zacks’ consensus estimate of $4.18 by $1.05. Regeneron Pharmaceuticals had a return on equity of 28.48% and a net margin of 20.41%. The business had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.50 billion. During the same period in the previous year, the company posted $3.04 earnings per share. The business’s revenue for the quarter was up 28.9% on a year-over-year basis. equities research analysts anticipate that Regeneron Pharmaceuticals will post 19.2 earnings per share for the current year.
In other news, Director Joseph L. Goldstein sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $325.60, for a total value of $325,600.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 10.80% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Steward Partners Investment Advisory LLC grew its holdings in Regeneron Pharmaceuticals by 495.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock worth $138,000 after acquiring an additional 307 shares during the period. Pin Oak Investment Advisors Inc. acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $152,000. Advisory Services Network LLC grew its holdings in Regeneron Pharmaceuticals by 147.0% during the fourth quarter. Advisory Services Network LLC now owns 447 shares of the biopharmaceutical company’s stock worth $168,000 after acquiring an additional 266 shares during the period. Vident Investment Advisory LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter worth $200,000. Finally, Mackenzie Financial Corp acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $204,000. 64.67% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “Canaccord Genuity Downgrades Regeneron Pharmaceuticals (REGN) to Hold” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/02/21/canaccord-genuity-downgrades-regeneron-pharmaceuticals-regn-to-hold.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.